AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809 · readout in 821 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Ventana Medical Systems, Inc.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Single · Treatment

Enrollment

1,100estimated

Sites

299

Countries

Australia, Belgium, Brazil +21

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-12-29

actual

When the study began enrolling

Primary completion

2028-11-17

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-12-27

estimated

The whole study's end, after follow-up

First posted

2025-10-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-21

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Epithelial Ovarian Cancer

Interventions

Drug: AZD5335
Drug: Mirvetuximab Soravtansine (MIRV) — also filed as Elahere
Drug: Paclitaxel — also filed as Taxol; Onxol
Drug: Pegylated liposomal Doxorubicin (PLD) — also filed as Doxil; Caelyx
Drug: Topotecan — also filed as Hycamtin

Primary outcome

what the primary-completion date above is the date OF

Progression free Survival (PFS)

measured Up to approximately 5 years

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed